

INTERNATIONAL SOCIETY
OF PAEDIATRIC ONCOLOGY

SOP
ASIA 2025

INTERNATIONAL SOCIETY OF PEDIATRIC ONCOLOGY

12nd - 15th Apr 2025

ALMAAREFA UNIVERSITY

RIYADH - KSA

Stronger Together

Strategic partner



جامعة المعرفة
ALMAAREFA UNIVERSITY



**EVENT
TROOP**
Event Management

WELCOME MESSAGE



Dr. Ali Alomari

President, Saudi Arabian Pediatric Hematology Oncology Society (SAPHOS)

Dear Participants,

Dear esteemed speakers, distinguished guests, and fellow pediatric oncology professionals,

On behalf of the Saudi Arabian Pediatric Hematology Oncology Society (SAPHOS), it is my great honor to extend a warm welcome to each and every one of you to the International Pediatric Oncology Society (SIOP) Asia Conference, taking place in Riyadh, Saudi Arabia, from April 12th to 15th, 2025.

We are thrilled to host this prestigious event, which brings together the world's leading experts in pediatric oncology, and provides a unique platform for knowledge sharing, collaboration, and networking. This conference is a testament to our collective commitment to advancing the field of pediatric oncology and improving outcomes for children with cancer worldwide.

The SIOP Asia Conference promises to be an exciting and enriching experience, featuring a comprehensive program of keynote lectures, plenary sessions, workshops, and poster presentations. Our esteemed speakers will share their latest research findings, innovative approaches, and best practices in pediatric oncology, covering a wide range of topics, from basic science to clinical applications.

As hosts, we are committed to ensuring that your experience in Riyadh is both productive and enjoyable. Our city has a rich cultural heritage, and we invite you to explore its many wonders, from the historic Diriyah district to the vibrant Riyadh Season festivities.

Once again, we extend our warmest welcome to you all. We look forward to sharing this unforgettable experience with you and to working together towards a brighter future for children with cancer.

Thank you, and welcome to Riyadh!

Sincerely,



WELCOME MESSAGE



Dr. Hiba AlTarrah

Chair, Local Organizing Committee SIOP Asia Congress 2025

Dear Participants,

As the Chair of the SIOP Local Organizing Committee, it is my great pleasure to welcome you to the 17th Annual SIOP Asia Congress, taking place in Riyadh from April 12-15, 2025. This conference aims to unite experts and practitioners in pediatric oncology, fostering collaboration and shared learning to enhance outcomes for children facing cancer. Our goal is to create a vibrant space for discussion, innovation, and partnership, ultimately driving progress in this critical field.

SIOP, and especially SIOP Asia, plays a vital role in advancing pediatric oncology through its commitment to collaboration and knowledge exchange. The contributions of the SIOP Asia community are invaluable, impacting both regional practices and the global pediatric oncology landscape.

Riyadh, as a city of the future, aligns perfectly with this vision. It is rapidly emerging as a hub for investment and innovation, in line with the Kingdom's Vision 2030, which aims to build a vibrant society and a thriving economy. Hosting this congress in such a dynamic city underscores our commitment to advancing healthcare and cultivating meaningful dialogue that can lead to transformative change.

Together, we can work towards our shared goal of improving treatment outcomes for children with cancer. In this spirit, let us embrace the theme of "Stronger Together," recognizing that collaboration is key to achieving better cures and making a lasting impact on the lives of our young patients.

Warm regards,



WELCOME MESSAGE



Dr. Ibraheem Abosoudah

Co-Chair, SIOP Asia Congress 2025

Distinguished Guests, Esteemed Colleagues,

Welcome to Saudi Arabia for SIOP Asia! As Co-Chair,

I'm honored to host this vital conference dedicated to advancing pediatric hematology and oncology.

This gathering reflects our shared commitment to improving children's lives.

We've curated a program rich with research and collaboration.

Saudi Arabia, embracing innovation, proudly facilitates this knowledge exchange.

Our focus: enhancing understanding, refining treatments, and improving outcomes.

Through presentations, we'll address regional challenges.

We thank all speakers, delegates, sponsors, and organizers. Your dedication makes this possible.

Please engage fully and enjoy Saudi Arabia's hospitality. We hope this conference is enriching.

Welcome to SIOP Asia!



Steering Committee



Dr. Ibraheem Abosoudah

Consultant Pediatric Hematology and Oncology and Blood and Marrow Transplant Medical Director of the Pediatric Hematopoietic Stem Cell Transplantation Program



Dr. Bader Al Hayani

Consultant Pediatric hematology and oncology at Kind Faisal Specialty Hospital and Research Center - Riyadh
Director of Pediatric Hematology and Oncology Fellowship Program at KFSHRC



Dr. Murtada Alsultan

Consultant, Pediatric Hematology Oncology and BMT



Dr. Mohammad Alshahrani

Consultant Pediatric Hematology/Oncology and BMT at Prince Sultan Military Medical City - Riyadh Head of pediatric BMT



Dr. Ali Alomari

Consultant pediatric Hematology/Oncology;
Head of Pediatric Hem/onc section,
Oncology center, King Saud University Medical City,
Riyadh;
President of Saudi Arabian pediatric Hematology
Oncology Society (SAPHOS).



Dr. Nawaf Al Khayat

Pediatric Oncology/ BMT consultant PSMMC



Prof. Wasil Jastaniah

MBBS, FAAP, FRCPC
Professor and Consultant Pediatric Hematology/Oncology/BMT;



Dr. Amani Alkofide

Consultant at Pediatric Hematology/Oncology Department King Faisal Specialist Hospital and Research Centre;
Member at the Children's Oncology Group (COG),



Scientific Committee



Dr.Sami Althubaiti

Consultant and Chairman of Pediatric Hematology Oncology Department, King Abdullah Specialized



Dr.Rawan Hammad

pediatric hematology/oncology and cancer genetics consultant, trained at the



Dr.Muhamed Saghir Khan

Co-Chair, SIOP Global Health Network (MD) is co chair of SIOP Global Health. Specialist Pediatric Hematology/Oncology Physician King Faisal Specialist Hospital and Research Center Al Madinah Al Munawarah, Saudi Arabia.

Members



Dr.Ali Balbaid

consultant pediatric radiation Oncologist working in King Fahad Medical City with more than 10 years experience in CNS and solid pediatric tumors and special interest in Proton Therapy.



Dr.Ibraheem Abosoudah

Consultant Pediatric Hematology and Oncology and Blood and Marrow Transplant Medical Director of the Pediatric Hematopoietic Stem Cell Transplantation Program



Dr. Nahlah Alkarim

Pediatric Clinical Dietitian



Dr.Elena Ladas

Columbia University Irving Medical Center (CUIMC) - Sid and Helaine Lerner Professor of Global Integrative Medicine in the Division of Pediatric Hematology/Oncology/Stem Cell Transplant



Dr.Aeshah AlAzmi

Assistant Director pharmacy services, King Abdullah Specialized Children Hospital-Jeddah, Ministry of National Guard Health Affairs;



Shonsise Young

Professional Registered Nurse. Initial specialisation ICU and solid organ transplantation.



Dr.Hana Aljulaih

Consultant Pediatrician, Pediatric Hematology Oncology, Hemoglobinopathy - U of T, Qatif Health Network



Dr.Hassan Altrabolsi

Consultant, Pediatric Hematology / Oncology, Stem cell Transplantation and Cellular Therapy.



Scientific Committee



Dr. Abdulrahman Alsultan

Professor of Pediatric Hematology and Oncology and Stem cell transplant at King Saud University

Members



Dr. Eric Bouffet

Emeritus Professor of Paediatrics at the University of Toronto and former Head of the Neuro-Oncology Section in the Division of Haematology/Oncology at the Hospital for Sick Children, Toronto (2000-2022).



Dr. Murali Chintagumpala

Dr. Murali is the Director of the Clinical Neuro-oncology Program at Texas Children's Cancer Center, Baylor College of Medicine.



Dr. Akira Nakagawara

MD, PhD, is President Emeritus of the Saga HIMAT Foundation in Japan.



Dr. Asim Belgaumi

Hub Director for the Eastern Mediterranean region at St. Jude Children's Research Hospital.



Dr. Ramandeep Arora

Consultant Pediatric Oncologist at Max Healthcare, Honorary Medical Advisor at Cankids India, and Director of INPHOG.



International advisors



Dr. Murali Chintagumpala

Dr. Murali is the Director of the Clinical Neuro-oncology Program at Texas Children's Cancer Center, Baylor College of Medicine.



Dr. Eric Bouffet

Emeritus Professor of Paediatrics at the University of Toronto and former Head of the Neuro-Oncology Section in the Division of Haematology/Oncology at the Hospital for Sick Children, Toronto (2000-2022).



Dr. Asim Belgaumi

Hub Director for the Eastern Mediterranean region at St. Jude Children's Research Hospital.



Dr. Ramandeep Arora

Consultant Pediatric Oncologist at Max Healthcare, Honorary Medical Advisor at Cankids India, and Director of INPHOG.



Dr. Akira Nakagawara

MD, PhD, is President Emeritus of the Saga HIMAT Foundation in Japan.



Dr. Gevorg Tamamyan

President-Elect, Professor and Chairman of Hematology and Pediatric Oncology at Yerevan State Medical University (YSMU), and CEO of the Immune Oncology Research Institute.



Moderators



Dr. Abdullah Baothman

Pediatric Hematology Oncology and Bone Marrow Transplantation Consultant,
Assistant Professor at King Saud bin Abdulaziz University for Health Sciences,



Dr. Shaker Abdullah

Consultant Pediatric Hematology / Oncology & BMT
King Faisal Specialist Hospital & Research Centre.



Dr. Amani Alkofide

Consultant at Pediatric Hematology/Oncology Department King Faisal Specialist Hospital and Research Centre;
Member at the Children's Oncology Group (COG),



Dr. Nahla Mobarak

Consultant, Pediatric Neuro-oncology King Fahad Medical City KFMC Riyadh, KSA.



Dr. Naveed Ahmad

MBBS, MCPS, FCPS, MRCPI, FRCPI
Consultant Paediatric Oncologist
King Abdullah Specialised Children's Hospital
Riyadh, Saudi Arabia



Prof. Wasil Jastaniah

MBBS, FAAP, FRCPC
Professor and Consultant Pediatric Hematology/Oncology/BMT;



Dr. Dania Monagel

Associate Professor at King Saud Bin Abdulaziz for health Science; Consultant Pediatric Hematologist-Oncologist and BMT,



Dr. Hiroki Hori

Professor at Suzuka University of Medical Science, Japan.
SIOF continental President-Asia from 2021 to 2024.



Dr. Mohamad Ballourah

Consultant in Pediatric Hematology, Oncology, and Bone Marrow Transplantation,
King Faisal Specialist Hospital and Research Center.



Dr. Zaheer Ullah

Consultant Paediatric Oncologist
King Abdullah Specialized Children's Hospital,
King Abdulaziz Medical city.



Dr. Lulwah Abduljabbar

Radiation Oncologist at King Fahad Specialist Hospital-Dammam.



Dr. Ghufra Aljawi

Radiation Oncology Assistant Professor and Consultant,
King Saud bin Abdulaziz University for Health Sciences,
affiliated with National Guard Health Affairs,
Jeddah, Saudi Arabia.





Dr. Asim Belgaumi

Interim Chief Medical Informatics Officer
The Aga Khan University, Pakistan;
Hub Director for Eastern Mediterranean region
St. Jude Children's Research Hospital.



Dr. Mohammed Essa

Deputy chairman Pediatric Hematology /
Oncology Section head,
Pediatric stem cell transplantation and cellular
therapy, King Abdullah Specialist Children hospital
, Ministry of National Guard - Riyadh



Dr. Abdulaziz Alghamdi

Pediatric Radiation Oncologist
King Faisal Specialist Hospital in Riyadh.



Dr. Afshan Aziz

Pediatric Hematologist/Oncologist;
Chairman, Department of Pediatrics,
King Faisal Specialist Hospital & Research Centre;



Dr. Saad Al Daama

Consultant PHO&SCT,
Executive Director of Medical and Clinical affairs,
KFSH.



Dr. Eman AlShamsi

Consultant and the Head
The Pediatric Hematology Oncology Department
Al Jalila Children's Specialty Hospital



Dr. Guillermo Chantada

Pediatric Oncologist
In Charge of the Outreach Program of the
Pediatric Cancer Center Barcelona (PCCB)
The Hospital Sant Joan de Déu (Barcelona, Spain



Dr. Aeshah AlAzmi

Assistant Director pharmacy services,
King Abdullah Specialized Children
Hospital-Jeddah,
Ministry of National Guard Health Affairs;



Dr. Ibrahim Ghemlas

Acting Chairman, Pediatric Hematology Oncology
department,
Consultant Pediatric Hematology Oncology,
King Faisal Specialist Hospital and Research
Centre (Gen.Org.)- Riyadh;



Dr. Mohammed Sajid Qureshi

Formally-Trained Paediatric Neuro-Oncologist and
Cancer Geneticist,
Associate Member of the Brain Tumor Research Center,
Assistant Professor at the University of Toronto.



Dr. Nisreen amayiri


Pediatric Neuro-Oncologist at King Hussein
Cancer Center (KHCC), Jordan, where she has
led the neuro-oncology service since 2011.



Dr. Ali Balbaid

consultant pediatric radiation Oncologist working
in King Fahad Medical City with more than
10 years experience in CNS and solid pediatric
tumors and special interest in Proton Therapy.





Dr. CHI KONG LI

Research Professor in the Department of Paediatrics at The Chinese University of Hong Kong and an Honorary Consultant at Hong Kong Children's Hospital.



Dr. Purna Kurkure

Head - Division of Pediatric Haemato-Oncology & Bone Marrow Transplant (BMT), SRCC Children's Hospital



Dr. Rashmi Dalvi

Chair, SIOP Advocacy Committee
APHOG : Steering committee member & Global Health/Advocacy Chair



Dr.Scott Howard

CEO, Resonance (ResonanceHealth.org)
Deputy Director, Yeolyan Hematology Center (blood.am/eng)
Senior Advisor, Pediatric Cancer and Blood Disorders Center of Armenia
International Development Officer,



Dr.Elena Ladas

Columbia University Irving Medical Center (CUIMC) - Sid and Helaine Lerner Professor of Global Integrative Medicine in the Division of Pediatric Hematology/Oncology/Stem Cell Transplant



Dr.Akira Nakagawara

MD, PhD, is President Emeritus of the Saga HIMAT Foundation in Japan.



Dr.Godfrey Chi-Fung Chan

Clinical Professor, The University of Hong Kong (HKU) (since 2009)



Dr.Nahlah Alkarim

Pediatric Clinical Dietitian



Dr.Abdulrahman Alsultan

Professor of Pediatric Hematology and Oncology and Stem cell transplant at King Saud University



Dr.Saadiya Khan

Physician Pediatric Onc-BMT. With a special interest in Palliative Care and Quality Care;
Consultant Pediatric



Dr.Murtada Alsultan

Consultant, Pediatric Hematology Oncology and BMT



Dr.Omar Chamdine

A pediatric hematologist-oncologist with a subspecialization in pediatric neuro-oncology. Particular interest in research related to pediatric CNS tumors and global child health.





Dr.Ali Alshehri

Consultant pediatric hematology and oncology.
KSUMC-oncology Centre .Riyadh



Dr.Mohamed Ashour

Clinical Pharmacy Specialist, Ped. Hem. Onc.
King Faisal Specialist Hospital



Dr.Fahd Almanjomi

Consultant pediatric Hematology oncology/BMT at
king Fahd medical city Riyadh



Dr.Khaled Alghamdi

Associate Professor of Pediatrics
Alfaisal University
Consultant Pediatric Complex and Palliative Care



Dr.Omar Alsharif

Consultant of Pediatric
Hematology&Oncology/BMT
Head Division of pediatric Oncology/BMT
Deputy of pediatric Department
prince sultan Military Medical city
(PSMMC),Riyadh
Assistant professor, Alfaisal University



Dr.Qasim Alharbi

Consultant, Pediatric Hematology, Oncology and SCT
King Fahad Specialist Hospital at Dammam, Saudi Arabia



Dr.Bharat Agarwal

Prof Emeritus & Former Head of Department,
Dept of Pediatric Hematology & Oncology, B.J.
Wadia Hospital for Children, Parel, Mumbai



Dr.Ali Alharbi

Associate Professor & PHO Consultant King
Abdulaziz University Hospital (KAUH), Jeddah



Dr.Yasser Alfraih

Assistant Processor and Consultant Pediatric Surgeon
at King Saud University in Riyadh, Saudi Arabia.





Dr.Ahmed Farrag



Dr.Sanjeeva Gunasekera



Dr.Osama Almosallm



Dr.Benson Pau



Dr.Carl Queiros



Dr.Roula Farah



Dr.Issarang Nuchprayoon



Dr.Mayya Assaad



Dr.Osman Mansur



Dr.Awatif Alanazi



Dr.Hadiehsadat Eslampanahseyedi

Pediatric Oncology & Stem Cell Transplant Consultant.
Head , Pediatric Solid Tumor Section
Director, Pediatric Stem Cell Transplant & Cellular
Therapy Fellowship Training Program



Speakers



Dr. Gevorg Tamamyan

President-Elect, Professor and Chairman of Hematology and Pediatric Oncology at Yerevan State Medical University (YSMU), and CEO of the Immune Oncology Research Institute.



Dr. Kirill Kirgizov

Deputy Director for Science and a Leading pediatric hematologist/oncologist (Head of the largest Russian Bone Marrow Transplant Program) Nikolay Blokhin National Medical Research Center



Dr. Wasil Jastaniah

Professor and Consultant Pediatric Hematology/Oncology/BMT; Chairman of the Department of Oncology King Faisal Specialist Hospital & Research Center (KFSH&RC) in Jeddah, Saudi Arabia.



Dr. Deepak Bansal

Professor, Pediatric Hematology-Oncology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Editor-in-Chief: Pediatric Hematology Oncology Journal



Dr. Jolia Mehany

Child Life Specialist with a background in Recreational Therapy. Started the First Child Life Program in Oncology and BMT in Saudi Arabia. PedsCaree



Dr. Daniel Indelicato

Tenured Professor and Associate Vice Chair the University of Florida Department of Radiation Oncology; Director of the pediatric proton therapy fellowship program,



Dr. Ali Alomari

Consultant pediatric Hematology/Oncology; Head of Pediatric Hem/onc section, Oncology center, King Saud University Medical City, Riyadh; President of Saudi Arabian pediatric Hematology Oncology Society (SAPHOS).



Dr. Wen Shen Looi

Radiation Oncologist Proton Therapy SG, Singapore Institute of Advanced Medicine; Clinical Teacher in the Lee Kong Chian School of Medicine. Consultant in the Division of Radiation Oncology, National Cancer Centre Singapore;



Dr. Anirban Das

Formally-Trained Paediatric Neuro-Oncologist and Cancer Geneticist, Associate Member of the Brain Tumor Research Center, Assistant Professor at the University of Toronto.



Dr. Vitaly Smelov

Medical Officer in the Cancer team of the Special Initiative on NCDs and Innovation The WHO Regional Office for Europe.



Dr. Akihiro Yoneda

Deputy Director, Children's Cancer Center, Surgeon-in-Chief, Division of Surgery, Department of Surgical Specialties,



Dr. Nabil Ahmed

Research Member, The Dan L Duncan Cancer Center, Professor (tenure-track), Department of Pediatrics,





Dr. Malak Al Thgafi

Professor, Vice chair for International Programs,
Director of Neuropathology Services and
Fellowship Programs
Emory University.



Dr. Michael Pulsipher

Division Chief, Pediatric Hematology
Intermountain Primary Children's Hospital;
Director of the Children's and Adolescent Cancer Initiative,
Huntsman Cancer Institute



Dr. Naveed Ahmad

Consultant Paediatric Oncologist
King Abdullah Specialised Children's Hospital
Riyadh, Saudi Arabia.



Dr. Mohamed Abdelbaki

Director of the Pediatric Neuro-Oncology Program
St. Louis Children's Hospital (SLCH);
Associate Professor of Pediatrics
Washington University School of Medicine in
St. Louis - Missouri (USA)



Dr. Sunil Bhat

Radiation Oncologist
Proton Therapy SG, Singapore Institute of Advanced
Medicine; Clinical Teacher in the Lee Kong Chian School of
Medicine; Consultant in the Division of Radiation Oncology,
National Cancer Centre Singapore;



Dr. Bilal Qureshi

Pediatric Radiation Oncologist;
Head of Radiation Oncology Section, Assistant
Professor, Aga Khan University, Karachi, Pakistan.
Co-Chair of PROS Working Group of SIOP Global Health
Network (GHN);
Global Scholar of St Jude Children's Research Hospital.



Dr. Hiroshi Fuji

Radiation Oncologist,
National Hospital Leading Pediatric
Oncology in Japan;
Member at SIOP, SIOP Asia and Pediatric
Radiotherapy Oncology Society (PROS).



Dr. Abdelhafeez Abdelhafeez

Pediatric Oncology Surgeon,
Associate Professor,
University of Rochester; Directed fellow program in
pediatric oncology surgery in 3 continents



Dr. Hiroki Hori

Professor at Suzuka University of Medical Science,
Japan.
SIOP continental President-Asia from 2021 to 2024.



Dr. Muhammad Shamvil

Senior Consultant Pediatric Oncology,
Executive Director Medical Services at Indus
Hospital & Health Network (IHNN)



Dr. Catherine Lam

St. Jude Children's Research Hospital - Founding
Director, WHO Collaborating Centre for Childhood
Cancer; Director, Health Systems Unit & Asia Pacific
Regional Program, St. Jude Global



Dr. Murali Chintagumpala

Dr. Murali is the Director of the Clinical Neuro-oncology
Program at Texas Children's Cancer Center, Baylor College
of Medicine.





Dr. Naureen Mushtaq

Dr. Naureen Mushtaq is an Associate Professor and Section Head of Pediatric Oncology/Hematology at Aga Khan University Hospital, Pakistan.



Dr. Mushabbab Asiri

Professor Mushabbab Al Asiri, is the General Director of the National Cancer Center in the Saudi Health Council and a Consultant Clinical and Radiation Oncologist at King Fahad Medical City.



Dr. Michael Fisher

Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania



Dr. Stephen Hunger

Chief of the Division of Oncology, Director of the Center for Childhood Cancer Research, and Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics at the Children's Hospital of Philadelphia.



Dr. Motohiro Kano

Dr. Kano is a Pediatric Surgeon at Keio University School of Medicine, specializing in pediatric oncology and cancer research.



Dr. Akira Nakagawara

MD, PhD, is President Emeritus of the Saga HIMAT Foundation in Japan.



Dr. Eric Bouffet

Emeritus Professor of Paediatrics at the University of Toronto and former Head of the Neuro-Oncology Section in the Division of Haematology/Oncology at the Hospital for Sick Children, Toronto (2000-2022).



Dr. Ramandeep Arora

Consultant Pediatric Oncologist at Max Healthcare, Honorary Medical Advisor at Cankids India, and Director of INPHOG.



Dr. Spandana Rayala

Pediatric Palliative Care specialist at Bayt Abdullah Children's Hospice, Kuwait.



Dr. Nita Radhakrishnan

Additional Professor and Head of the Department of Pediatric Hematology Oncology at the Post Graduate Institute of Child Health, Noida, India.



Dr. Saba Mazhar

Manager of Pharmacy (Training & Development) at Shaukat Khanum Memorial Trust, Pakistan



Dr. Venkatraman Radhakrishnan

Professor and Head of the Department of Medical and Pediatric Oncology at the Cancer Institute (W.I.A), Adyar, Chennai.





Dr. Giuseppe Troisi

MD, MPH, is a Technical Officer at the WHO Regional Office for the Eastern Mediterranean, Department of NCDs and Mental Health.



Dr. Norbert Graf

Professor Emeritus of Pediatrics at Saarland University, Germany, Principal Investigator of the UMBRELLA protocol for childhood kidney tumors and an Associated International Member of the Children's Oncology Group (COG).



Dr. Hawazen Alsaedi

Consultant at King Faisal Specialist Hospital and Research Center (KFSHRC) in Riyadh, specializing in Bone Marrow Transplantation (BMT), CAR T-Cell Therapy, and Immunology.



Dr. Eman Eldebawy

Professor of Radiation Oncology at the National Cancer Institute, Cairo University, Egypt since December 2022.



Dr. Abdulrahman Alsultan

Professor of Pediatric Hematology and Oncology and Stem cell transplant at King Saud University



Dr. Hong Pheng Amos Loh

chairs the VIVA-KKH Paediatric Brain and Solid Tumour Programme



Dr. Janine Stutterheim

Pediatric oncologist at the Princess Maxima Center, specialized in childhood acute lymphoblastic leukemia.



Dr. Fahd Al Sufiani

Consultant Anatomical Pathology with sub-speciality in Neuropathology and Paediatric Pathology. Interested in education, quality, and leadership.



Dr. Nahlah Alkarim

Pediatric Clinical Dietitian



Dr. Simone de Campos

Full professorship in Pediatric Surgery - Federal University of São Paulo - Brazil



Dr. Aeshah A. AlAzmi

Consultant Pediatric Oncology/Hematology/Bone Marrow Transplant (BMT) Clinical Pharmacist and Assistant Director at King Abdullah Specialist Hospital (KASCH), MNGHA, Jeddah, Saudi Arabia.



Dr. Suradej hongeng

Vice Dean of Special Affairs, Faculty of Medicine, Ramathibodi Hospital, Mahidol University





Dr. Ali AlAhmari

the Section Head of Pediatric Stem Cell Transplantation and Cellular Therapy and Director of the Histiocytosis Program at King Faisal Specialist Hospital and Research Center (KFSHRC)



Dr. Ruzanna Papyan

Chief, Pediatric Oncology Department, Pediatric Cancer and Blood Disorders Center of Armenia Assistant Professor, Department of Pediatric Oncology and Hematology, Yerevan State Medical University



Afaf Almutairi

Assistant Head Nurse for the Pediatric Oncology Infusion Center and outpatient clinics at King Faisal Specialist Hospital and Research Centre.



Dr. Kimikazu Matsumoto

Director of the Children's Cancer Center at the National Center for Child Health and Development, Japan.



Wedad Awad

Senior Critical Care Clinical Pharmacist at the King Hussein Cancer Center (KHCC) in Jordan



Dr. Laura Lee Dupuis

Associate Senior Scientist, Research Institute; a Health Clinician Scientist,



Dr. Sameh Awwad

Consultant Clinical Pharmacist at King Fahad Medical City (KFMC), Riyadh, specializing in pediatric oncology and parenteral nutrition.



Dr. Sinam Papyan

General Pediatrician at Arabkir Medical Center.



Nuha Mahdi

Critical care nurse senior specialist Master on oncology 10 years experience Clinical instructor and program director



Dr. Benshang Li

CHIEF PHYSICIAN & DIRECTOR, CELL THERAPY CENTER, SHANGHAI CHILDREN'S MEDICAL CENTER (SCMC), SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE



Dr. Miho Kato

Chief Physician, Department of Childhood Cancer Data Management, National Center for Child Health and Development (NCCHD), Tokyo, Japan



Cesar Maderazo

King Faisal Specialist Hospital and Research Center, Saudi Arabia - Nurse in Medical/Radiation Oncology and Palliative Care Units (2018-Present)





Nouf Shwikan

Oncology Nurse Specialist and a Nurse Clinician in KFSH Jeddah



Dr. Nisreen amayiri

Pediatric Neuro-Oncologist at King Hussein Cancer Center (KHCC), Jordan, where she has led the neuro-oncology service since 2011.



Dr. Mohammed AlMotairi

Consultant Hematology/Oncology Clinical Pharmacist from King Fahad Medical City and Clinical Assistant



Dr. Gaurav Narula

Professor Pediatric Oncology & Health Sciences and Project Lead for the CAR T & Cell Therapy Center at Tata Memorial Center Mumbai.



Yousef Musleh

Hematology/BMT clinical instructor in King Faisal specialist hospital Riyadh



Wesam Nayef AlMomani

Distinguished Oncology Nurse Educator and a sub-specialty in Oncology Nursing.



Marwa Elhadidy

Specialized Pediatric Hematology Oncology and HSCT clinical pharmacist currently working at King Faisal Specialist Hospital and Research Center-Jeddah (KFSHRC-J)



Shara Alharbi

Clinical Specialist in Pediatric Oncology



Neamah Farhan

Clinical Nurse Specialist



Dr. Jaume Mora

scientific director of the Pediatric Cancer Center Barcelona (PCCB) at HSJD a pediatric oncologist with a PhD in Molecular Oncology since 2003. After residency training in general pediatrics (1992-1995)



Dr. Rehana Punjwani

Director Nursing at Dow University hospital and a free lance Trainer and Program Manager for Pediatric Oncology Nursing training and trainer for palliative care Projects.



Dr. Abeer Almudaihim

Consultant Clinical Dietitian based in Riyadh, Saudi Arabia. She currently serves part-time at the Ministry of National Guard - Health Affairs, where she coordinates communication and partnerships between clinical nutrition departments and provides nutrition care for outpatients





Dr. Michael Sullivan

Professor of Paediatric Oncology in the Department of Paediatrics, University of Melbourne, and a Senior Specialist Consultant Paediatric Oncologist/Neuro-Oncologist in the Children's Cancer Centre, Royal Children's Hospital, Melbourne.



Dr. Hsiu-Ju Yen

Pediatric hematology oncologist in treating children with blood disorders and malignancies. She completed her residency in pediatrics, then specialized in pediatric hematology and oncology through the fellowship at TPVGH.



Dr. Preeya Bajaj

King Faisal Specialist Hospital and Research Center, Saudi Arabia - Nurse in Medical/Radiation Oncology and Palliative Care Units (2018-Present)



Dr. Valiev Timur



Dr. Ushakova Tatiana



Dr. Carlos Rodriguez-Galindo

Carlos Rodriguez-Galindo, MD
Executive Vice President
Director, St. Jude Global
Chair, Department of Global Pediatric Medicine
Associate Director, Community Outreach and Engagement, St. Jude Comprehensive Cancer Center



Dr. CHI KONG LI

Research Professor in the Department of Paediatrics at The Chinese University of Hong Kong and an Honorary Consultant at Hong Kong Children's Hospital.



Dr. Purna Kurkure

Head - Division of Pediatric Haemato-Oncology & Bone Marrow Transplant (BMT), SRCC Children's Hospital



Dr. Rashmi Dalvi

Chair, SIOP Advocacy Committee
APHOG : Steering committee member & Global Health/Advocacy Chair



Dr. Khaled Alghamdi

Associate Professor of Pediatrics
Aldaisal University
Consultant Pediatric Complex and Palliative Care



Dr. Elena Ladas

Columbia University Irving Medical Center (CUIMC) - Sid and Helaine Lerner Professor of Global Integrative Medicine in the Division of Pediatric Hematology/Oncology/Stem Cell Transplant



Dr. Guillermo Chantada

Pediatric Oncologist
In Charge of the Outreach Program of the Pediatric Cancer Center Barcelona (PCCB)
The Hospital Sant Joan de Déu (Barcelona, Spain)





Dr. Asim Belgaumi

Hub Director for the Eastern Mediterranean region at St. Jude Children's Research Hospital.



Dr. Scott Howard

CEO, Resonance (ResonanceHealth.org)
Deputy Director, Yeolyan Hematology Center (blood.am/eng)
Senior Advisor, Pediatric Cancer and Blood Disorders Center of Armenia
International Development Officer,



Dr. Godfrey Chi-Fung Chan

Clinical Professor, The University of Hong Kong (HKU) (since 2009)



Dr. Marilys Corbex

WHO Senior technical officer (P5) - WHO Regional Office for Europe, Copenhagen, Denmark



Dr. Yongmin Tang

Academic leader of the Division/Center of Pediatric Hematology/Oncology at Children's Hospital of Zhejiang University School of Medicine.



Dr. Abdullah Alhammad

Consultant Pediatric Body and Neuroradiologist
Section Head Pediatric Radiology
Deputy Chairman, Medical Imaging - KASCH





Noura Alowaidi



Diana Bushnak



Dr.Yizhuo Zhang



Dr.Siddhartha Laskar



Dr.Stephan Grupp



Dr.Karen Goddard



Dr.Kara Kelly



Dr. Dalal Aldegthaither



Norah Alabdulrahman



Dr. Yazeed Alshihayb



Dr.Abdullah Alharbi



Dr.Latifah Al-Arfaj



Dr.Yaser Khafaga



Dr.Najma Shaheen



Dr.Farrah Bashir





Dr.Abdullah Khan



Dr.Mohammed Alnamshan



Dr.Nikita Mahakal



Dr.Cuddles Foundation



Dr.Yenn Ang



Dr.Keith Teo



Dr.Karishma Pavaskar



Dr.Andrea Cuiello



Dr.Roula Farah



Dr.Uma Seshadri



Dr.Rahmi Lestari



Dr.Ritu Bhalla



Dr.Cankids Kidscan



Dr.Yayasan Anyo



Dr.Jodie Sim



INTERNATIONAL SOCIETY
OF PAEDIATRIC ONCOLOGY

SOP
ASIA 2025

**INTERNATIONAL
SOCIETY OF
PEDIATRIC
ONCOLOGY**

12nd - 15th Apr 2025

ALMAAREFA UNIVERSITY

RIYADH - KSA

Stronger Together



Scientific Program



EDUCATIONAL DAY

12 APRIL 2025

Educational Day			
Time		Topic	Speaker
07:30	08:30	Registration	
Track 1		DiSPLeN Hematologic Malignancies - Burkitt Lymphoma	Moderators: Mohammad ALshahrani (KSA)/ Venkatraman Radhakrishnan (India)
08:30	08:35	Case Presentation	Yazeed Alshihayb (KSA)
08:35	08:55	Presentation 1: Burkitt Lymphoma - Lessons from the past	Asim Belgaumi (Pakistan)
08:55	09:15	Presentation 2: Tumor Lysis Syndrome	Scott Howard (USA)
09:15	10:30	Panel Discussion	Valiev Timur (Russia), Mohammed Sajid Qureshi (India), Deepak Bansal (India), Najma Shaheen (Pakistan)
10:30	11:00	Coffee Break	
Track 1		DiSPLeN Hematologic Malignancies - Hodgkin Lymphoma	Moderators: Sami Althubaiti (KSA)/Scott Howard (USA)
11:00	11:05	Case Presentation	Latifah Al-Arfaj (KSA)
11:05	11:25	Presentation 1: Updates on Management of Advanced Hodgkin Lymphoma	Valiev Timur (Russia)
11:25	11:40	Presentation 2: Updates on Radiation Therapy in Advanced Stage Hodgkin Lymphoma	Bilal Qureshi (Pakistan)
11:40	13:00	Panel Discussion	Abdelhafeez Abdelhafeez, Venkatraman Radhakrishnan (India)
13:00	14:00	Lunch Break & Prayer Break	
Track 1		DiSPLeN Hematologic Malignancies - Acute Lymphoblastic Leukemia	Moderators: Ahmed Farrag (Egypt) / Ali Algiraigri (KSA)
14:00	14:20	Presentation 1: Updates on Management of B Cell ALL	Stephen Hunger (USA)
14:20	14:40	Presentation 2: Strategies to improve outcomes in low resource settings	Scott Howard (USA)
14:40	16:00	Panel Discussion	Kirill Kirgizov (Russia), Deepak Bansal (India), Sami Althubaiti (KSA)
16:00	16:30	Coffee Break	
Track 1		Joint Session	
16:30	17:00	CureAll Showcase	Cath Lam (USA) and Khilola Rustamova (Uzbekistan)



EDUCATIONAL DAY

12 APRIL 2025

17:00	17:15	SIOP/St. Jude ARIA Beneficiaries	Michael Sullivan
17:15	18:00	Conclusion and Feedback	DiSPLeN Team/All speakers and Moderators
Track 2		DiSPLeN Solid Tumors - Wilms Tumor	Moderators: Garik Sagoyan (Russia)/Naveed Ahmad (KSA)
08:30	08:40	Case Presentation	Abdullah Alharbi (KSA)
08:40	09:00	Presentation 1: General Approach for the management of Wilms Tumor	Norbert Graff (Germany)
09:00	09:15	Presentation 2: Surgical approach for advanced Wilms Tumor	Hafeez Abdul Hafeez (USA)
09:15	09:30	Presentation 3: Radiation therapy updates	Bilal Qureshi (Pakistan)
09:30	10:30	Panel Discussion:	Zaheer Ullah (KSA), Ali Balbaid (KSA), Shamvil Ashraf (Pakistan), Purna Kurkure (India), Eman Alshamsi (UAE)
10:30	11:00	Coffee Break	
Track 2		DiSPLeN Solid Tumors - Retinoblastoma	Moderators: Amani Alkofide (KSA), and Rashmi Dalvi (India)
11:00	11:05	Case Presentation	
11:05	11:20	Presentation 1: Updates on management of Advanced Retinoblastoma	Ushakova Tatiana (Russia)
11:20	11:35	Presentation 2: Intra-arterial chemotherapy	Amani Alkofide (KSA)
11:35	11:50	Presentation 3: Local control modalities for retinoblastoma	Abdullah Khan (KSA)
11:50	13:00	Panel Discussion	Deepak Bansal (India), Shamvil Ashraf (Pakistan), Sidrath Laskar (India), Yaser Khafaga (KSA)
13:00	14:00	Lunch Break & Prayer Break	
Track 2		DiSPLeN Solid Tumors - Brain Tumor	Moderators: Naureen Mushtaq (Pakistan)/Rawan Hammad (KSA)
14:00	14:05	Case Presentation	Farrah Bashir (Pakistan)
14:05	14:25	Presentation 1: Whom to refer to a child with suspected CNS tumor- LMIC Perspective	Eric Bouffet (Canada)
14:25	14:40	Presentation 2: Neuro Oncologic Emergencies	Michael Sullivan (Australia)
14:40	14:55	Presentation 3: Radiation therapy in infant brain tumors	Abdulaziz Alghamdi (KSA)
14:55	16:00	Panel Discussion	Amani Alkofide (KSA), Nisreen Amayiri (Jordan), Omar Chamdine (KSA), Daniel Indelicato (USA)
16:00	16:30	Coffee Break	



EDUCATIONAL DAY

12 APRIL 2025

Track 3		Clinical Trials & Cancer Registry	Moderators: Miho Kato (Japan), Venkatraman Radhakrishan (India)
14:00	14:10	Presentation 1: Establishing Cancer Registries	Asim Belgaumi (Pakistan)
14:10	14:30	Presentation 2: Setting up a Data Center	Miho Kato (Japan)
14:30	14:45	Challenges in conducting Clinical Trials in LMICs	Venkatraman Radhakrishan (India)
14:45	16:00	Panel Discussion	Godfrey Chi-Fung Chan (Hong Kong), Scott Howard (USA), Catherine Lam (USA), Hiba AlTarrah (KSA)

CCI Asia Program - Day 1 (with 2 interactive trainings) - 12 April (Saturday) - all CCI participants including survivors Venue: Workshop 4-6 (Basement 02)			
08:00-09:00		Registration (Ground Floor), Arrival, Meet & Greet	
09:00-09:30		Welcome & Flag Parade Ice Breaking	Moderator: Benson Pau
Track 4		Session 1 - Innovations In Psychosocial Support And Supportive Care	Moderator: Hadieh Eslampanahseyedi, Patrick Yip
09:30	09:45	S1.1 Deployment of Multimedia Tools to Improve Nutrition Counseling and Education amongst Caregivers of Pediatric Oncology Patients in India	Nikita Mahakal, Cuddles Foundation, India
09:45	10:00	S1.2 Photovoice Journeys of Childhood Cancer Survivors	Yenn Ang & Keith Teo, Children's Cancer Foundation, Singapore
10:00	10:15	S1.3 Effect of Expressive Therapies on Quality of Life of Paediatric Cancer Caregivers through Online Support Groups	Karishma Pavaskar, Cancer Patients Aid Association, India
10:15	10:30	Q&A	
10:30	11:00	Coffee Break	
Track 4		Interactive Training	
11:00	13:00	Interactive Training Session (A) Workshop 1: Palliative Care Training - Moderators: Jodie Sim & Roula Farah	Andrea Cuvillo, St Jude Global Representative



EDUCATIONAL DAY

12 APRIL 2025

		CCI Global Representative	
13:00	14:00	Lunch Break & Prayer Break	
14:00	16:00	Interactive Training Session (B) Workshop 2: Nutrition Support Training - Moderators: Benson Pau	Uma Seshadri, Nikita Mahakal Cuddles Foundation
16:00	16:30	Coffee break	
Track 4		Session 2 - Free Papers	Moderators: Ming Ming Lee, Rahmi Lestari Adi Putra
16:30	16:45	S2.1 Ensuring Educational Continuity for Cancer Impaired Children: A Five-Year Analysis of CanKids Scholarship Program	Ritu Bhalla, Cankids Kidscan, India
16:45	17:00	S2.2 Anyo Foundation Support for Children with Cancer	Pinta Manullang-Panggabean, Yayasan Anyo Indonesia, Indonesia
17:00	17:15	S2.3 Experience in the Scientific Research Grant Program	Malak Al-Thaqafi, SANAD, Saudi Arabia
17:15	17:20	Speakers memento presentation for Session 2	



DAY 01

13 APRIL 2025

Day 1 Sunday, 13 April 2025

Day 1 Sunday, 13 April 2025			
Time		Topic	Speaker
07:00	08:00	Registration	
Track 1		Inaugural Session	Presenter: Murtada Alsultan
08:00	08:05	Video (Quraan) & National Anthem	
08:05	08:10	Welcome remarks from SAPHOS Chair	Ali Alomari (KSA)
08:10	08:15	Welcome Remarks	Hiroki Hori (Japan)
08:15	08:20	LOC Chair	Hiba AlTarrah & Ibraheem Abosoudah (KSA)
08:20	08:25	Message From SIOP Asia President	Gevorg Tamamyan (Armenia)
08:25	08:30	Message From SIOP President	Guillermo Chantada (Spain)
08:30	08:35	Message from the National Cancer Center of Saudi Arabia	Meshabeb Asiri (KSA)
08:35	09:00	Local Sanad performance & group picture	
Keynote Lecture 1: Moderators: Ibraheem Abousoudah			
09:00	09:30	Current Landscape of Childhood Cancer in Asia: Challenges and Opportunities	Hiroki Hori (Japan)
09:30	09:40	Discussion	
09:40	10:10	Coffee Break & Exhibition Viewing	
Track 1		Session: Cancer Genetics & Brain Tumors	Moderators: Qassim Alharbi & Omar Chamdine
10:10	10:30	NF1 Optic Pathway Glioma: Management and The Importance of Visual Assessment	Michael Fisher (USA)
10:30	10:50	Latest updates on CMMRD from the IRRDC	Anirban Das (Canada)
10:50	11:10	Surveillance in Limited-Resource Settings	Nisreen Amayiri (Jordan)
11:10	11:25	Cancer Predisposition in Saudi Arabia	Nahla Mobarak (KSA)
11:25	11:40	Q&A	
11:40	12:40	AstraZeneca- NF1 Plexiform Neurofibroma Management and Treatment Outcomes	Michael Fisher (USA)
12:00	13:20	Lunch break & Poster Viewing	
Track 1		Session: Neuro-Oncology	Moderators: Amani Al-kofide & Shaker Abdullah.
13:20	13:40	Building a Neuro-Oncology Program: Pakistan Experience	Naureen Mushtaq (Pakistan)



DAY 01

13 APRIL 2025

13:40	14:00	Molecular Diagnostics in Pediatric Brain Tumors: The Challenges	Malak Althagafi (USA, Virtual)
14:00	14:20	Infant Brain Tumor	Eric Bouffet (Canada)
14:20	14:40	Low-grade Glioma Therapeutic Options	Murali Chintagumpala (USA)
14:40	15:00	Brain Repair and Rehabilitation	Eric Bouffet (Canada)
15:00	15:20	Q&A	
15:20	15:50	Coffee Break & Exhibition Visit	
Track 1		Session: Free Paper Session 1	Moderators: Nisreen Amayiri & Abdulrahman Alsultan
15:50	16:00	SIOP - 079: Hepatocellular Carcinoma in Children and Adolescents: Results of a Retrospective Analysis	Sevil Babakhanova (Russia)
16:00	16:10	SIOP - 088: Long-Term Efficacy and Safety of Larotrectinib in Pediatric Patients with Primary CNS And Non-Primary CNS TRK Fusion Tumors	Omar Chamdine (KSA)
16:10	16:20	SIOP - 142: The role of circulating GD2 as a diagnostic tumor biomarker for Neuroblastoma (pilot project)	Nikolay Ivanov (Russia)
16:20	16:30	SIOP - 148: Surgical treatment of cervical and cervicomedialastinal Neuroblastomas and Ganglioneuroblastomas in children.	Raisa Oganessian (Russia)
16:30	16:40	SIOP - 179: Reirradiation for Pediatric Central Nervous System Tumors: LQ Model Vs Real Clinical Practice. Comparison Of Dose to Critical Structures and Clinical Outcome	Nataliia Martynova (Russia)
16:40	16:50	SIOP - 187: Utility of CSF Cytology study in Pediatric Parameningeal Rhabdomyosarcoma at initial diagnosis- Is this an essential staging investigation in all?	Kumar Arghya Prasanna Mondal (India)
16:50	17:00	SIOP - 189: Prognostic impact of dissemination in pediatric Low-Grade Gliomas and Glioneuronal tumors: a decade of experience at Tata Memorial Centre, Mumbai.	Duhita Sengupta (India, Virtual)
17:00	17:10	SIOP - 213: Factors Impacting Abandonment in Patients with Newly Diagnosed Retinoblastoma in India: Analysis from Inphog-Rb-19-01 Study	Amita Mahajan (India)
17:10	17:50	Q&A	



DAY 01

13 APRIL 2025

Track 2		Session: Access to Care - Opportunities & Challenges in Asia	Moderators: Abdullah Baothaman & Scott Howard
10:10	10:25	Community Outreach and Education to Improve Early Detection and Access to Pediatric Cancer Care	Shamvil Ashraf (Pakistan, Virtual)
10:25	10:50	Multidisciplinary Team Science: From Tumor Boards to Networks in Asia Pacific and South Asia	Catherine Lam (USA)
10:50	11:15	Challenges in Access to Clinical trials in Asia	Chi-kong Li (China)
11:15	11:40	Drug shortage- Challenges in Asia	Ramandeep Arora (India)
11:40	12:00	Q&A	
12:00	13:20	SAPHOS/UMBRELLA meeting (12:00-13:00)	Lunch break & Poster Viewing
Track 2		Session: Leukemia	Moderators: Mohamad Walid Ballourah & Fahd Almanjomi
13:20	13:40	Treatment of Infant ALL, what is new?	Janine Sutterheim (Netherlands)
13:40	14:00	Treatment of Low-Risk ALL	Stephen Hunger (USA)
14:00	14:20	Leukemia in Down's Syndrome	Wasil Jastaniah (KSA)
14:20	14:40	How we treat: Pediatric AML treatment in Low-Resource Settings	Deepak Bansal (India)
14:40	15:00	Improving Outcomes in Childhood Acute Lymphoblastic Leukemia (ALL) in India through clinical trials	Venkatraman Radhakrishnan (India)
15:00	15:20	Q&A	
15:20	15:50	Coffee Break & Exhibition Viewing	
Track 2		Session: Bone Marrow Transplantation & Cellular Therapy	Moderators: Dania Monagel & Ibrahim Ghemlas
15:50	16:10	Optimizing Conditioning Regimens for Haploidentical Transplantation for Malignant Disorders	Michael Pulsipher (USA)
16:10	16:30	Haplo-identical Stem Cell Transplant in Hemoglobinopathies	Sunil Bhat (India)
16:30	16:50	Gene Therapy for Sickle Cell Anemia	Stephan Grupp (USA)
16:50	17:05	How to Optimize the Cure for Thalassemia	Suradej Hongeng (Thailand)
17:05	17:20	Hematopoietic Stem Cell Transplant for Primary Immunodeficiency Disorders	Hawazen Alsaedi (KSA)
17:20	17:30	Q&A	
17:30	18:10	Cellular Therapies for Hemoglobinopathies: The Saudi Experience	Mohammed Aleissa (KSA)



DAY 01

13 APRIL 2025

Track 3		Session: Nursing	Moderator: Shonise Young
10:10	10:25	Precision Medicine in Pediatric Leukemia - Nursing Implication and Challenges	Neamah Farhan
10:25	10:45	Implementing MIBG Therapy for High-Risk Neuroblastoma: Nursing Roles	Diana Bushnak
10:45	11:00	Assessment and Management of Patient Fatigue	Wesam Nayef
11:00	11:15	Assessing Patient and Family needs in Oncology - Research Study (local)	Amna ALSHELALI
11:15	11:30	Skin Toxicities - Identification and Management	Nouf Shwikan
11:30	11:45	Baseline Nursing Standards For Pediatric Oncology	Rehana Punjwani
11:45	12:00	Q&A	
12:00	13:20	Lunch Break & poster viewing	
Track 3		Session: Nursing	Moderator: Amna Alshelali
13:20	13:40	Quality of Life of Care Givers	Nuha Mahdi
13:40	14:00	Neutropenic Sepsis - Challenges and Strategies	Ebtesam Almutairi
14:00	14:20	Impact of Nurse-Led Clinics on patient satisfaction	Shara Alharbi
14:20	14:40	PHO Patient Journey - A Pathway to Patient Engagement and Improved Outcomes	Noura Alowaidi
14:40	15:00	The Role of Nurses in Survivorship	Shenila Ali
CCI Asia Program			
CCI Asia Program - Day 2, 13 April (Sunday)			
Venue: Workshop 4 - 6 (Basement 02)			
08:00	09:00	SIOP Asia Congress Inaugural Session (CCI Participants to Join at the Main Stage at Basement 01)	
09:00	09:10	CCI Participants, please kindly move back to the CCI Conference Hall (Workshop 4-6 at Basement 02)	
Track 4		Session 3 - CCI Opening	Moderator: Benson Pau
09:10	09:15	Opening Message: CCI Asia 2025 Conference Co-Chair	Jodie Sim
09:15	09:20	Opening Message: SIOP Asia 2025 Congress Chair	Hiba Al-Tarrah
09:20	09:25	Opening Message: CCI LOC, SANAD Chair	HRH Princess Adelah bint Abdullah bin Abdulaziz Al Saud
09:25	09:30	Opening Message: WHO representative	Giuseppe Troisi
09:30	09:35	Opening Message: SIOP Asia President	Gevorg Tamamyan
09:35	09:40	Opening Message: CCI Vice President	Alejandra Mendez



DAY 01

13 APRIL 2025

09:40	10:10	coffee break	
Track 4		Session 4 - WHO GICC Collaborations and Actions in Eastern Mediterranean Region	Moderator: Roula Farah
10:10	10:30	Regional Updates and Way Forward for Global Initiative for Childhood Cancer: Eastern Mediterranean Region	Giuseppe Troisi, WHO Technical Officer (cancer control), Noncommunicable Disease Prevention, UHC/Noncommunicable Diseases and Mental Health (NMH), WHO EMRO Cairo, Egypt
10:30	10:50	Panel Discussion with invited guests from WHO EMRO, CCI members from GICC Focus countries and countries with GICC activities in EMR.	
Track 4		Session 5 - Compassionate Journeys: Advancing End-of-Life Care, Grief Support, and Bereavement Services	Moderators: Issarang Nuchprayoon, Mayya Assaad
10:50	11:05	S5.1 Walking with Families for the first time in Lebanon: Transforming End-of-Life Care Support at CCCL	Sarah Wehbe, Children Cancer Center of Lebanon, Lebanon
11:05	11:20	S5.2 Hope and Healing: Care in Palliative and After	Shu Shan Wong, Sarawak Children's Cancer Society, Malaysia
11:20	11:35	S5.3 Supporting families in End-of-Life Care, Grief Support, and Bereavement	Roula Farah, CHANCE Association, Lebanon
11:35	11:50	Q&A / Speakers memento presentation for Session 4 & 5	
12:00	13:20	Lunch break	
Track 4		Sessions 6 - Advancing Fundraising: Innovating for Impact	Moderators: Carlos Queiros, Osman Mansur
13:20	13:35	S6.1 Crowd funding strategy for kids: a partnership with an adult cancer organization	Issarang Nuchprayoon, Wishing Well Foundation, Thailand
13:35	13:50	S6.2 Successfully engage the community to attract and retain small sum donors over long period in monthly web-based donation program	Benson Pau, Guangzhou Gold-ribbon Special Children Parents Center, China
13:50	14:05	S6.3 How CSR integrated with up to date technologies correlated with fundraising to promote childhood cancer care?	Hadieh Eslampanah, MAHAK, Iran



DAY 01

13 APRIL 2025

14:05	15:05	S6.4 Fundraising Workshop	Alejandra Mendez, CCI Vice-President, Chile
15:05	15:10	Speakers memento presentation for Session 6	
15:10	15:20	Summary of the Day	Jodie Sim, CCI Asia 2025 Conference Co-Chair
15:20	15:50	Coffee Break	
Track 4		Session 7 - Collaborative Pathways for Childhood Cancer Survivors (CCI-SIOP Nurse-Survivor Joint Session)	Moderators: Rehana Punjwani, Bindu Nair
15:50	15:55	Session introduction	
15:55	16:10	S7.1 Thriving Beyond Cancer: Building Bridges to Healthcare Accessibility for Rural Communities	Mandakini , DigiSwasthya Foundation, India
16:10	16:25	S7. 2 Parents lived experience with child with cancer	Yousef Musleh, King Faisal Specialist Hospital and Research Centre, Saudi Arabia
16:25	16:40	S7.3 Collaborative Approaches in Redefining Survivorship Care within the Community	Preeya Bajaj, Children's Cancer Foundation, Singapore
16:40	16:55	S7.4 The Power of Words: Successfully Turning Pain Into Inspiration	Siti Zarrahmawati, Cancer Buster Community (YOAI), Indonesia
16:55	17:10	S7.5 Survivorship initiative from CCI global and Asia	Patrick Yip, CCI Asia
17:10	17:40	Panel Discussion - Multidisciplinary Perspective on survivorship	Scott Howard (Physician), Yousef Musleh (Nurse), Patrick Yip (Survivor), Alejandra Mendez (Parent) Memento presentation for Session 7
CCI Asia Survivors Meeting - Day 2, 13 April (Sunday) Venue: Workshop 3 (Basement 02)			
Track 5		Morning Session	
10:00	10:10	Opening remarks Opening Message	Benson Pau Patrick Yip
10:10	10:30	Introduction Session	
10:30	11:00	Ice-breaking Session	
11:00	12:00	Interactive Session	
12:00	13:20	Lunch and networking	
Track 5		Afternoon Session	



DAY 01

13 APRIL 2025

13:20	13:35	Tobacco Product Use and Exposure in Childhood Cancer Survivors in India: A mixed methods study	Ritu Bhalla, CanKids...KidsCan, India
13:35	13:50	Collaborative Pathways for Childhood Cancer Survivors	Dima El-Mekkawi, Children's Cancer Center of Lebanon, Lebanon
13:50	14:10	Addressing the needs of Childhood Cancer Survivors in Low and Middle Income Countries - The Next Frontier	Dr Ramandeep Singh Arora, Member, Governance Council India Childhood Cancer IniBaBve, India
14:10	14:15	Q&A / Speakers memento presentation	
14:15	15:15	Projects Brainstorming	
15:15	15:20	Closing: Summary, Key Takeaways & Way Forward for CCIASN	



DAY 02

14 APRIL 2025

Day 2 Monday, 14 April 2025

Day 2 Monday, 14 April 2025			
Track & time		Session & Topic	Moderator & Speaker
Track 1		Session: Bridging the Gap in Precision Oncology	Moderators: Abdulrahman Alsultan & Nahla Mobark
07:30	07:45	Advances in Precision Oncology in Pediatric Rhabdomyosarcoma	Yizhuo Zhang (China)
07:45	08:05	Targeted Therapies in Childhood Lymphomas	Scott Howard (USA)
08:05	08:25	Precision Oncology in LMIC	Nisreen Amayiri (Jordan)
08:25	08:50	The Impact of Precision Medicine on Pediatric Brain Tumors	Mohammed Abdelbaki (USA)
08:50	09:00	Q&A	
Keynote lecture 2: Moderator: Hiroki Hori			
09:00	09:30	Global Efforts to Accelerate Progress in Childhood Cancer Care and Control	Carlos Rodriguez Galindo (USA)
09:30	09:40	Discussion	
09:40	10:10	Coffee Break & Exhibition Viewing	
Track 1		Session: Leukemia & Lymphoma	Moderators: Murtada Alsultan & Saadiya Khan
10:10	10:30	NGS-sequencing MRD as a diagnostic tool for the management of Pediatric ALL	Yongmin Tang (China)
10:30	10:50	Therapeutic Drug Monitoring in Leukemia and Lymphoma	Scott Howard (USA)
10:50	11:10	How I Treat Hodgkin Lymphoma: The North American Approach	Kara Kelly (USA, virtual)
11:10	11:25	Relapsed Hodgkin's Lymphoma Therapeutic Options	Kara Kelly (USA, virtual)
11:25	11:40	Pediatric Mature B-cell Non-Hodgkin Lymphoma in LMIC setting	Asim Belgaumi (Pakistan, Virtual)
11:40	12:00	Q&A	
12:15	13:15	NexPoS Referral Pathways & Systems meeting	
12:00	13:20	Lunch Break & poster viewing	
Track 1		Session: Survivorship & Late Effects	Moderators: Khaled Alghamdi & Zaheer Ullah
13:20	13:45	Long-Term Follow-Up and Care Strategies for Childhood Cancer Survivors	Chi Kong Li (China)
13:45	14:10	Enhancing Survivorship and Quality of Life for Childhood Cancer Patients: Insights from Asia	Purna Kurkure (India)
14:10	14:30	Fertility Preservation for Pediatric Cancer Patients	Kimikazu Matsumoto (Japan)



DAY 02

14 APRIL 2025

14:30	14:50	Safeguarding Survivors: Preventing Treatment-Related Toxicity in Pediatric Cancer Patients	Laura Lee Dupuis (Canada, virtual)
14:50	15:00	Q&A	
15:00	15:50	Coffee Break & Exhibition Viewing	
Track 1		Session: Free Paper Session 2	Moderators: Zaheer Ullah & Shaker Abdullah
15:50	16:00	SIOP -043: Implication of Post-Induction Minimal Residual Disease In The Management Of Pediatric Acute Lymphoblastic Leukemia In Resource-Limited Setting	Waqar Mushtaq (Pakistan)
16:00	16:10	SIOP - 051: Rearrangements of The KMT2A Gene In Acute Leukemia In Children - Determination In Whole Genome Sequencing Data And Clinical Application	Elena Zerkalenkova (Russia)
16:10	16:20	SIOP - 308: The Role of TPMT and NUDT-15 Genetic Polymorphisms in 6-Mercaptopurine Dose Tolerability among Pediatric B-Cell ALL Patients in Saudi Arabia	Walid Ballourah (KSA)
16:20	16:30	SIOP - 160: Optimizing Implementation of Comfort Measures in Pediatric Oncology: A Quality Improvement Initiative in Indus Hospital and Health Network Karachi, Pakistan	Alina Rahim (Pakistan)
16:30	16:40	SIOP - 214: The germline genetic testing in children with DICER1 - associated benign and malignant tumors: a 6-year single-center experience	Maria Skvortsova (Russia)
16:40	16:50	SIOP - 288: Sharing Insights from the National Pediatric Radiotherapy Peer Review Meetings in Pakistan	Maria Tariq (Pakistan)
16:50	17:00	SIOP - 319: Impact of Nursing Basic Central Line Seminar on the Rates of Central Line-Associated Bloodstream Infections (CLABSI) at the University of the Philippines - Philippine General Hospital	Catherine Remeticado (Philippines)
17:00	17:10	SIOP- 341-Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Leukemia: Single Center Experience in 150 Pediatric Patients Transplanted in 2021-2023	Irina Kostareva (Russia)
17:10	17:50	Q&A	



DAY 02

14 APRIL 2025

17:10	17:50	Q&A	
Track 2		Radiation Oncology	Moderators: Ali Balbaid & Ghufuran Aljawi
07:30	07:45	The State of Pediatric Radiotherapy in the Region - Access to Technology	Bilal Qureshi (Pakistan)
07:45	08:00	The role of proton therapy in CNS tumors	Daniel Indelicato (USA)
08:00	08:15	Palliative Radiotherapy in Pediatric Oncology: Approaches, Challenges, and Outcomes	Eman Eldebawy (Egypt)
08:15	08:30	Establishing the Late Effects, Assessment, and Follow-Up (LEAF) Clinic: A Comprehensive Program for Cancer Survivors	Karen Goddard (Canada, virtual)
08:30	08:45	Outcomes of definitive radiation therapy in Pediatric Sarcomas	Siddhartha Laskar (India, Virtual)
08:45	09:00	Q&A	
09:40	10:10	Coffee Break & Exhibition Viewing	
Track 2		Session: Supportive Care & Palliative Care	Moderators: Aeshah AlAzmi & Eman Alshamsi
10:10	10:25	Ototoxicity and the evidence behind Sodium Thiosulfate	Michael Sullivan (Australia)
10:25	10:40	Psychosocial Support in Oncology	Jolia Mehany (KSA, Virtual)
10:40	10:55	Supportive Care in HSCT & Cellular Therapy	Kirill Kirgizov (Russia)
10:55	11:10	Cultural Challenges and Best Practices in Pediatric Palliative Care in Oncology	Spandana Rayala (Kuwait, Virtual)
11:10	11:25	The Neutropenic Diet and Food Restrictions in Oncology and Stem Cell Transplant	Elena Ladas (USA)
11:25	11:40	Q&A	
11:40	12:00	Inpharmus- Protecting Young Ears: Strategies to Prevent Cisplatin-Induced Hearing Loss in Pediatric Cancer Patients	Michael Sullivan (Australia)
12:00	13:00	SIOP Asia Business Meeting	
12:00	13:20	Lunch Break & poster viewing	
Track 2		Session: Solid Tumors	Moderators: Afshan Aziz & Awatif Alanazi
13:20	13:40	Advances in Neuroblastoma treatment	Jaume Mora (Spain)
13:40	14:00	Current Strategies in the Management of Pediatric Neuroblastoma: The Japanese Experience	Akihiro Yoneda (Japan)
14:00	14:20	Inpharmus- Humanized Anti-GD2 Naxitamab: A New Era for High-Risk Neuroblastoma Patients	Jaume Mora (Spain)
14:20	14:40	Recent advances in Vascular Tumors	Godfrey Chi-Fung Chan (Hong Kong)



DAY 02

14 APRIL 2025

14:40	15:00	Advances in Retinoblastoma Management: From Diagnosis to Survivorship	Guillermo Chantada (Spain)
15:00	15:20	Q&A	
15:25	15:55	Coffee Break & Exhibition Viewing	
Track 2		Session: Solid Tumors and Local Control	Moderators: Lulwah Abduljabbar, Abdulaziz Alghamdi & Mohammed Sajid Qureshi
15:50	16:10	Modern Radiotherapy for Pediatric Sarcomas	Wen Shen Looi (Singapore)
16:10	16:30	Advances in Radiation Therapy in Solid Tumors	Hiroshi Fuji (Japan)
16:30	16:50	Global Collaboration in Pediatric Oncology Surgery	Simone Abib (Brazil)
16:50	17:10	New Technologies in Minimally Invasive Surgery in Childhood Cancer Surgery	Abdelhafeez Abdelhafeez (USA)
17:10	17:30	Pediatric Solid Tumors with Intravascular Expansion	Simone Abib (Brazil)
17:30	17:45	Q&A	
Track 3		Pediatric Surgical Oncology Updates- IPSO session 1	Moderators: Abdelhafeez Abdelhafeez (USA), Osama Almosallm , Ali Alyahya
07:30	07:35	Opening	All
07:35	08:05	Advancements in Wilms Tumor Surgery	Simone Abib (Brazil)
08:05	08:35	Advancements in Soft Tissue Surgery	Mohammed Sajid Qureshi (Indai)
08:35	09:00	Advancements in Hepatoblastoma Surgery	Abdelhafeez Abdelhafeez (USA)
09:40	10:10	Coffee Break & Exhibition Viewing	
Track 3		Pediatric Surgical Oncology Updates- IPSO session 2	Moderators: Abdelhafeez Abdelhafeez (USA) , Yasser AlFraih
10:00	10:30	Advancements in Neuroblastoma Surgery	Amos Loh (Singapore)
10:30	11:00	Advancement in Germ cell tumor surgery	Simone Abib (Brazil)
11:00	11:30	Multidisciplinary Collaboration and Quality Improvement	Amos Loh (Singapore)
11:30	12:00	Advancements in Image-Guided Tumor Resection	Abdelhafeez Abdelhafeez (USA)
12:00	12:30	Q&A	
12:00	13:20	Lunch Break & poster viewing	
Track 3		Session: Nutrition	Moderators: Elena Ladas & Nahlah Alkarim
13:20	13:40	Keynote: Microbiome and Metabolome	Elena Ladas (USA)
13:40	14:00	Diet Diversity and Nutrition Status in survivors of Cancer	Nita Radhakrishnan (India)



DAY 02

14 APRIL 2025

14:00	14:20	Developing a Nutrition Program for Pediatric Cancer Patients: Lessons from Armenia	Sinam Pappan (Armenia)
14:20	14:40	Impact of Nutritional Intake and Microbiome Dynamics on Treatment Outcomes in Pediatric ALL Patients in Riyadh, Saudi Arabia	Abeer Almudaihim & Dalal Aldeghaither (KSA)
14:40	15:00	Nutritional Challenges in Pediatric Neuro-Oncology	Nahlah Alkarim (KSA)
15:00	15:20	Q&A	
Track 4		Session: Nursing Central Venous Access Device Management	
08:00	08:20	Reduction of CLABSI rates in PHO Units in a Tertiary Hospital	Maryah Abuamarah
08:20	08:40	Strategies and Interventions to reduce accidental Central Line removal or dislodgement	Afaf Almutairi
08:40	10:10	Workshop: Central Line Management	Cesar Maderazo & Norah
10:10	10:25	Q&A	
Track 4		Session: Pharmacology: Empowering Pediatric Oncology Pharmacists by Networking and Collaboration	Moderator: Mohamed Ashour
13:25	13:45	Beyond the Basics: A clinical Pharmacist’s Deep Dive into Blinatumomab	Marwa Elhadidy (KSA, Virtual)
13:45	14:05	HLH management and future directions	Mohammed Al Motairi (KSA)
14:05	14:25	Managing Toxicities and Side Effects: Role of Pharmacists in Supportive Care	Wedad B. Awad (Jordan, Virtual)
14:25	14:45	Medication related Challenges in Pediatric Patients undergoing HSCT	Saba Mazhar (Pakistan, Virtual)
14:45	15:05	Transition of Inpatient Care: From Hospital to Home	Sameh Awwad (KSA)
15:05	15:25	Harmonization of Chemotherapy Protocols to Bedside: Role of Clinical Pharmacist	Aeshah AlAzmi. (KSA)
15:25	15:40	Q&A	
CCI Asia Program			
CCI Asia Program - Day 3, 14 April (Monday)			
Venue: Workshop 4-6 (Basement 02)			
Track 5		Session 8 - Amplifying Awareness and Advocacy: Harnessing Emerging Trends, AI, and Social Media for Impactful Action	Moderator : Alejandra Mendez
08:30	08:45	S8.1 Innovative Advocacy for Pediatric Cancer: Leveraging AI, Emerging Trends, and Social Media	Lavaniyah Ganapathy, Children Cancer Association Malaysia, Malaysia



DAY 02

14 APRIL 2025

08:45	09:00	S8.2 Leveraging Social Media and AI-Driven Platforms for Targeted Childhood Cancer Awareness and Advocacy: The King Hussein Cancer Foundation's Approach	Majd Al Qudah, King Hussein Cancer Foundation, Jordan
09:00	09:15	S8.3 Hope Amidst Chaos: Supporting Childhood Cancer Care Amid Lebanon's Crisis	Sarah Wehbe, Children's Cancer Center of Lebanon, Lebanon
09:15	09:30	S8.4 Patient Education Factsheets on Childhood Cancer and Essential Medicines Through International Collaboration: A Case Study in Mongolia	Tsetsegsaikhan Batmunkh, National Cancer Council of Mongolia, Mongolia
09:30	09:40	Q&A / Speakers memento presentation for Session 8	
09:40	10:10	Coffee Break	
Track 5		Session 9 - CCI Updates	Moderators: Benson Pau & Carl Queiros
10:10	10:40	CCI Global Update	
		CCI Asia Update - CCI Asia Regional Committee: Portfolio Presentation	
10:40	11:40	'Communications & Awareness, ENLACE Asia, Knowledge & Research Utilisation, Membership Development, Resource Mobilisation & Financing, Survivor Network Development, Strategic Partnership & Advocacy, Asia Conference - Announcement of the next conference	
11:40	11:55	Interactive Session with members + CCI Asia Annual Business Meeting	
11:55	12:00	Closing	Benson Pau
13:00	17:00	CCI Committee Meeting	



DAY 03

15 APRIL 2025

Day 3 Tuesday, 15 April 2025

Day 3 Tuesday, 15 April 2025					
Track & time		Session & Topic		Moderators & Speakers	
Track 1		Session: Bridging the Gap in Immunotherapy		Moderators: Mohammed Aleissa & Wasil Jastanaiah	
07:30	07:45	Immunotherapy for Childhood Hematological Malignancies: Established Approaches and Future Directions		Michael Pulsipher (USA)	
07:45	08:00	CAR T-Cell Therapy: Experience from Saudi Arabia.		Ali Aahmari (KSA)	
08:00	08:15	CAR T-cell Therapy: The Chinese Experience		Benshang Li (China)	
08:15	08:30	Increasing the Accessibility of Affordable CAR T-cell Therapy in India		Gaurav Narula (India, Virtual)	
08:30	08:45	CAR T-cell Therapy in Brain Tumors		Nabil Ahmed (Texas, USA)	
08:45	09:00	Q&A			
Keynote lecture 3 - Moderators: Dr. Amani Alkofeidi					
09:00	09:30	Cure is Not Enough: Reflections on the Long-Term Follow-Up of Survivors from a Pediatric Brain Tumor		Eric Bouffet (Canada)	
09:30	09:40	Discussion			
09:40	10:10	Coffee Break & Exhibition Viewing			
Track 1		Session: Solid & Brain Tumors		Moderators: Ali Alshehri & Omar Alsharif	
10:10	10:30	Advanced Stage Wilms Tumor		Norbert Graf (Germany)	
10:30	10:50	Relapsed Wilm’s Tumor		Naveed Ahmad (KSA)	
10:50	11:10	Lessons from Rare Tumors		Catherine Lam (USA)	
11:10	11:30	The Latest Clinical trials in Central Nervous System Germ Cell Tumors across the World		Mohamed Abdelbaki (USA)	
11:30	11:45	Approach to Extracranial Germ Cell Tumor		Motohiro Kano (Japan)	
11:45	12:00	Q&A			
12:00	13:20	Lunch Break & poster viewing			
Track 1		Session: Regional and International Collaborations		Moderators: Saad Al Daama & TBD	
13:20	13:35	ARIA: Adapted Therapy for Childhood Cancers		Michael Sullivan (Australia)	
13:35	13:50	St Jude’s Led Global Initiatives		Carlos Rodriguez Galindo (USA)	
13:50	14:05	Cancer Inequalities in Pediatric Oncology 1		Vitaly Smelov & Marylis Corbex (WHO Europe)	



DAY 03

15 APRIL 2025

14:05	14:20	Cancer Inequalities in Pediatric Oncology 2	Giuseppe Troisi (WHO Middle East)
14:20	14:35	Pediatric Oncology East Mediterranean (POEM)- Initiatives to Improve Outcomes.	Gevorg Tamamyan (Armenia)
14:35	14:50	SIOP's Advocacy Programs	Rashmi Dalvi (India)
14:50	15:05	CureAll: Progress and Opportunities in our Shared Global Initiative	Catherine Lam (USA)
15:05	15:20	APHOG: Access to Clinical Trials in Asia	Akira Nakagawara (Japan)
15:20	15:35	Q&A	
Track 2		APHOG Session 1: Toward the Future: Better Cure and Care for the Solid Tumors in Asia	Moderators: Godfrey Chan and Akira Nakagawara
07:30	07:45	APHOG Prospects of International Collaboration from the Organizational Aspects: Childhood Cancer Registration and Data Management	Miho Kato (Japan)
07:45	08:00	Cocktail Immunotherapy Strategies for Neuroblastoma	Godfrey Chan (Hong Kong)
08:00	08:15	POEM-OS Study- the First Multicenter Study on Osteosarcoma in the POEM Region	Ruzanna Papyan (Armenia)
08:15	08:30	Surgical Management of Pediatric Solid Tumor in Asia: Regional Challenges and Solutions	Akihiro Yoneda (Japan)
08:30	08:45	Radiation Therapy Advances for Pediatric Solid Tumors in Asia	Siddhartha Laskar (India)
08:45	09:00	Q&A	
09:40	10:10	Coffee Break & Exhibition Viewing	
Track 2		APHOG session 2: Toward the Future: Establishing the Structure and Blood Cancers	Moderators: Muhammad Saghir Khan, Hiroki Hori and Rashmi Dalvi. Moderators: Chi-Kong Li and Purna Kurkure
10:10	10:25	Results of the large-scale long-term follow-up in Taiwan. Introducing future collaboration idea	Hsiu-Ju Yen (Taiwan)
10:25	10:40	Possible Collaboration between APHOG and St. Jude Global on Childhood Cancer	Carlos Rodriguez-Galindo (USA)
10:40	11:25	Panel Discussion: Partnering among APHOG, POEM, SIOP, St. Jude Global and WHO for the sake of Pediatric Oncology in Asia	Gevorg Tamamyan, Vitaly Smelov, Godfrey Chan. Saghir Khan & Kirill Kirgizov
11:25	11:40	Pediatric Blood Cancer in Middle East Region	Sami AlThubaiti (KSA)



DAY 03

15 APRIL 2025

11:40	11:55	Clinical Trials in Pediatric HLH-related disorders in China	Yongmin Tang (China)
12:00	12:30	APHOG Annual Business Meeting (ABM) 2025 (12:00- 12:30 hrs)	
15:35	16:35	Closing Session/Acknowledgements/Awards	



OUR PARTNERS



المجلس الصحي السعودي
Saudi Health Council



Strategic partner



OUR SPONSORS

Platinum

inpharmus

Gold



Silver

AMGEN

Bronze

AstraZeneca

SERB
Pharmaceuticals

Exhibitor



Presenter

novo nordisk



RECORDATI
RARE DISEASES





Actor
portrayal

DANYELZA goes to work on their bones, while they start on their next symphony

High-risk neuroblastoma may still be in your child's bones or bone marrow if they have had an incomplete response[†] to their initial treatment or treatment after a relapse. Ask your care team if DANYELZA[®] could be the next step for your family.

*DANYELZA is still being studied to confirm the study results and the clinical benefit of treatment.

[†]Incomplete response is defined as partial response, minor response, or stable disease to prior therapy.

WHAT IS DANYELZA?

DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:

- has come back (relapsed) or that did not respond to previous treatment (refractory), **and**
- has shown a partial response, minor response, or stable disease to prior therapy.

It is not known if DANYELZA is safe and effective in children younger than 1 year of age.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about DANYELZA?

DANYELZA may cause serious side effects, including:

- **Serious infusion-related reactions.** DANYELZA can cause serious infusion-related reactions that require immediate medical attention. Infusion-related reactions are common with DANYELZA. Tell your healthcare provider right away if you get any signs or symptoms during or after your DANYELZA infusion, including: swelling of your face, eyes, lips, mouth, or tongue; itching; redness on your face (flushing); skin rash or hives; trouble breathing; cough or wheezing; noisy high-pitched breathing; and feeling faint or dizziness (low blood pressure)

- **Nervous system problems.** Talk to your healthcare provider right away if you have new symptoms or worsening of nervous system problems, including:

- Severe pain from nerves (neuropathic pain), including pain in the belly (abdomen), bone, neck, legs, or arms. Pain is common with DANYELZA and can be severe.

Please see pages 26-27 for additional **Important Safety Information**. Please see accompanying full **Prescribing Information and Patient Information** for DANYELZA including Boxed Warning on serious infusion-related reactions and nervous system problems, and talk to your doctor.

inpharmus



Not actual patient.

PEDMARK: the first and only FDA-approved therapy to reduce the risk of cisplatin-induced ototoxicity¹⁻³

For use in patients 1 month of age and older with localized, non-metastatic solid tumors¹

- The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours
- PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions because irreversible ototoxicity may have already occurred

PEDMARK is not substitutable with other sodium thiosulfate products.¹

Important Safety Information

- PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.
- Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.


Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Product Information on pages 15-26, or go to [PEDMARK.com](https://www.pedmark.com).

PEDMARK reduced the risk of hearing loss in patients with various types of localized disease in the COG ACCL0431 study conducted by the Children's Oncology Group^{1,10}

Study Design¹

- Multicenter, randomized, controlled, open-label study of 125 patients aged 1 to 18 years with solid tumors who were receiving a chemotherapy regimen for any stage disease that included a cumulative cisplatin dose of ≥ 200 mg/m²
- Patients were randomized 1:1 to receive cisplatin-based chemotherapy with PEDMARK (n=61) or without PEDMARK (n=64); individual cisplatin doses to be infused over ≤ 6 hours
- Efficacy analysis was performed on the ITT population of patients with localized disease only (n=77) in both the PEDMARK + cisplatin arm (n=39) and the cisplatin alone arm (n=38)
- Major efficacy outcome measure was hearing loss assessed by ASHA criteria. Hearing loss was assessed at baseline and 4 weeks after the final course of cisplatin

Underlying diagnosis among patients with localized disease¹



Important Safety Information

- The most common adverse reaction ($\geq 25\%$ with difference between arms of $>5\%$ compared to cisplatin alone) in COG ACCL0431 was hypokalemia.

Please see additional Important Safety Information throughout, and [full Prescribing Information](#), including Patient Product Information on pages 15-26, or go to [PEDMARK.com](#).




THE POWER OF PRECISION¹

ONE GENE. ONE EDIT. ONE TIME.*¹

A precise, autologous, one-time, gene-editing therapy¹ that has the potential to provide a functional cure to eligible patients^{2,3}

CASGEVY is indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).¹

CASGEVY is indicated for the treatment of transfusion-dependent β -thalassemia (TDT) in patients 12 years and older.¹



Visual for illustrative purposes only.

These preparations have several side effects. Please learn about them, consult your doctor or pharmacist, and read the medicine leaflet. If there are any side effects of the medications, please contact the General Food and Drug Authority to report on the unified number, 19999. For adverse events reporting please use this email: Vertexmedicalinfo@vrtx.com. For more information about Casgevy refer to the CASGEVY KSA SmPC.

*The treatment process includes mobilisation and apheresis, editing of the cells, myeloablative conditioning, CASGEVY administration and long-term follow-up.

References: 1. CASGEVY KSA Summary of Product Characteristics. 2. Eckrich MJ and Frangoul H. Semin Hematol. 2023;60(1):3-9 3. EMA. Assessment report: CASGEVY. Available at: https://www.ema.europa.eu/en/documents/assessment-report/casgevy-epar-public-assessment-report_en.pdf. Accessed May 2024

Marketing Authorisation Holder Vertex Pharmaceuticals (Europe) Limited 2 Kingdom Street, London, W2 6BD, United Kingdom

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Cigalah Healthcare Company, Al Akariya Building Number 2 Olaya Street, Riyadh 11533, Kingdom of Saudi Arabia. This promotional material is intended for healthcare professionals only.

To report any side effect(s):
- The National Pharmacovigilance Centre (NPC):
- SFDA Call Center: 19999
- E-mail: npc.drugs@sfda.gov.sa
- Website: <https://ade.sfda.gov.sa/>

CASGEVY is manufactured for Vertex Pharmaceuticals (Europe) Limited. Vertex, the Vertex triangle logo, CASGEVY, and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. © 2025 Vertex Pharmaceuticals (Europe) Limited [SA-72-2500019] 02/2025

For CASGEVY KSA summary of product characteristics, please scan the QR code





Company overview

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, we have a robust clinical pipeline of investigational small molecule, mRNA, cell and genetic therapies (including gene editing) in other serious diseases where we have deep insight into causal human biology, including sickle cell disease (SCD), beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease (AMKD), type 1 diabetes and alpha1- antitrypsin deficiency (AATD).

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 13 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Twitter and LinkedIn.



In patients with CD19-positive
Ph(-) B-cell precursor ALL

SET MORE PATIENTS ON THE PATH OF SUPERIOR, DURABLE, TRANSFORMATIONAL SURVIVAL

When integrated into frontline consolidation, BLINCYTO® redefined
the standard-of-care by delivering superior overall survival vs chemotherapy alone¹


The E1910 study was a multinational, randomized, controlled, phase 3 trial of BLINCYTO® alternating with chemotherapy vs chemotherapy alone in frontline consolidation in 224 newly diagnosed patients aged 30-70 years with Ph(-) B-cell precursor ALL. OS was calculated from time of randomization until death due to any cause.^{1,2} **3-year KM estimates for OS (primary endpoint) were 84.8% in the BLINCYTO® arm (n=112) vs 69.0% in the chemotherapy only arm (n=112); HR: 0.42 (95% CI: 0.24-0.75);* P = 0.003 (the stratified log-rank test).** Median follow-up was 3.6 years in both arms.¹ 5-year KM estimates for OS were 82.4% in the BLINCYTO® arm (n=112) vs 62.5% in the chemotherapy only arm (n=112); HR: 0.44 (95% CI: 0.25-0.76).^{1,1} Patients in the BLINCYTO® arm received 2 cycles of BLINCYTO®,¹ followed by 3 cycles of consolidation chemotherapy, then a third cycle of BLINCYTO®, followed by a fourth cycle of chemotherapy, and then a fourth cycle of BLINCYTO® (total 8 cycles).¹ Note: Patients randomized to the BLINCYTO® arm could proceed to HSCT after 1-2 cycles of BLINCYTO® and up to 2 cycles of consolidation chemotherapy.¹ Patients in the chemotherapy only arm received 4 cycles of consolidation chemotherapy.¹ Note: Patients randomized to the chemotherapy only arm could proceed directly to HSCT after intensification and up to 3 cycles of consolidation chemotherapy.¹ Additionally, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend blinatumomab as part of the ECOG1910 regimen, a preferred frontline treatment regimen for adult patients with Ph(-) B-cell precursor ALL.³

*The hazard ratio estimates are obtained from a stratified Cox regression model at the third interim analysis.¹ In a later analysis with a median follow-up of 4.5 years.¹ BLINCYTO® was administered as a continuous IV infusion at 28 mcg/day on Days 1-28.¹

Integrating BLINCYTO® into frontline consolidation delivered **improved 5-year KM estimates for OS** vs chemotherapy alone in patients with MRD negativity^{1,4}

- Primary endpoint was OS, 3-year KM estimates: 84.8% in the BLINCYTO® arm (n=112) vs 69.0% in the chemotherapy only arm (n=112); HR: 0.42 (95% CI: 0.24-0.75);* P = 0.003 (the stratified log-rank test). Median follow-up was 3.6 years in both arms. OS was calculated from time of randomization until death due to any cause¹
- Adding BLINCYTO® to frontline consolidation **reduced the risk of death from any cause by 58% vs chemotherapy alone in patients with MRD negativity¹**

OS in patients who were MRD(-)^{1,4}



- In a later analysis, median follow-up was 4.5 years in both the BLINCYTO® and chemotherapy only arms¹
- MRD was assessed centrally using standardized 6-color flow cytometry, with MRD(-) defined as < 0.01% leukemic cells in the bone marrow.² The MRD tests were performed at laboratory sites using assays that have not been analytically validated by FDA**

**NCCN
RECOMMENDED**

Blinatumomab is recommended by the National Comprehensive Cancer Network® (NCCN®) as part of **frontline consolidation** for both AYA and adult patients with Ph(-) B-cell precursor ALL **regardless of MRD status³**



Scan here to learn
more about the data and
key considerations

Don't wait, integrate BLINCYTO® into frontline consolidation¹

BLINCYTO® is a registered trademark of Amgen Inc.
© 2025 Amgen Inc. All rights reserved. USA-103-81886 02/25

AMGEN

SERB Pharmaceuticals is a growing pharmaceutical company and a dedicated ally to healthcare

providers treating patients facing rare conditions and emergencies.

We focus on providing unique solutions for Emergency Care providing broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks. This makes us a trusted partner and one-stop-shop for hospitals, healthcare systems,

first responders, emergency preparedness agencies, and non-profit organisations.

Also we focus on Rare Conditions by providing a growing portfolio helps patients with rare neurologic syndromes, metabolic disorders, and rare conditions in oncology. We work to help these patients get the diagnosis they need and access to the treatment options they deserve. This “patient first” culture has helped us to build long-term relationships with patient groups and key opinion leaders.

Our goal is to optimise every stage of the pharma value chain through a perfect balance of in-house capabilities and closely managed external partners. Our unique industry expertise allows us to determine what to do ourselves and what to outsource to trusted partners. This allows us to efficiently acquire, develop, manufacture, launch and com-

EFFECTIVE PROPHYLAXIS TAILORED TO PATIENTS' INDIVIDUAL NEEDS^{1,2}

In adults and adolescents* with severe haemophilia A, Esperoct® provides:

1 starting dose with the option to individualise^{**1}

50 IU/kg every 4 days, with the possibility of individualising dose and dosing interval based on achieved FVIII levels and individual bleeding tendency

≥5% FVIII activity levels and low ABR^{2,3}

≥5% FVIII activity levels predicted for 90% of the time[†] with a median total ABR^{††} of 0.84

30°–40°C stability to support patients' lifestyles^{1,4}

The only EHL rFVIII stable between 30° and 40°C for up to 3 months^{†1,4-7}

*In studies of previously treated patients, 12 years and above¹

**Prophylaxis: the recommended dose is 50 IU of Esperoct® per kg of body weight every 4 days. Adjustments of doses and administration intervals may be considered based on achieved FVIII levels and individual bleeding tendency¹

[†]3% mean trough levels observed^{1,2,8}

^{††}Total ABR for all bleeds, including spontaneous and traumatic bleeds²

^{†††}Refer to Esperoct® SmPC for full storage conditions¹

References

1. Esperoct® Summary of Product Characteristics.
2. Giangrande P *et al.* *J Thromb Haemost* 2020; **18**:5–14.
3. Chowdary P *et al.* *Res Pract Thromb Haemost* 2019; **3**:542–554.
4. Napolitano M *et al.* *J Blood Med* 2021; **12**:9–20.
5. Adynovi® Summary of Product Characteristics, 2019.
6. Elocta® Summary of Product Characteristics, 2021.
7. Jivi® Summary of Product Characteristics, 2020.
8. Giangrande P *et al.* *J Thromb Haemost* 2017; **11**:252–261.

To report any side effect(s) or for more medical info please contact us:

- E-mail: nngulfsafety@novonordisk.com
- Website: <http://www.novonordisk.com.sa>

To report any side effect(s) please contact the National Pharmacovigilance

Centre (NPC):- E-mail: nngulfsafety@novonordisk.com
- SFDA call center: 19999 - E-mail: npc.drug@sfd.gov.sa
- Website: <https://ade.sfd.gov.sa/>

- In the event that there are comments on this materials, please contact SFDA: 19999

For more information about the product, please refer to the last approved Summary of product characteristics in KSA on Saudi Drugs Information system (SDI) website: (<https://sdi.sfd.gov.sa/>).

Success speaks for itself.¹⁻¹⁸

NovoSeven[®]: supporting your patients in **more indications** than any other agent¹⁹⁻²³

Recombinant
and rapid to use



of controlling
bleeds^{19,23}

Congenital
haemophilia A
with inhibitors

Congenital
haemophilia B
with inhibitors

Acquired
haemophilia

Surgery
(across all
indications)

Congenital FVII
deficiency

Glanzmann's
thrombastenia

sPPH



Rapid bleed control

- Rapid bleed control with consistently high efficacy¹⁹
- 77-93 % efficacy demonstrated across all indications^{9,19,24-27}



Favourable safety profile

- Works locally at the site of vascular injury^{19,28}
- Low (0.28 %) rate of thrombotic events across indications^{1,29,30}



Convenience

- Rapid reconstitution and administration¹⁹
- Room temperature stable for portability¹⁹
- 24 hour stability post-reconstitution at 25 °C in a 50 ml syringe (polypropylene) for administration via infusion pump^{17,19}

References:

1. Neufeld EJ et al. *Blood Rev.* 2015;**29**(S1):S34-S41. 2. Santagostino E et al. *Thromb Haemost.* 2006;**4**(2):367-371. 3. Neufeld EJ et al. *Pediatr Blood Cancer.* 2013;**60**(7):1178-1183. 4. Pruthi RK et al. *Thromb Haemost.* 2007;**98**(4):726-732. 5. Shapiro AD et al. *Thromb Haemost.* 1998;**80**(5):773-778. 6. Parameswaran R et al. *Haemophilia.* 2005;**11**(2):100-106. 7. Hay CR et al. *Thromb Haemost.* 1997;**7**(8):1463-1467. 8. Amano K et al. *Haemophilia.* 2016;**23**(1):50-58. 9. Baudo F et al. *Blood* 2012;**120**(1):39-46. 10. Borel-Derlon A et al. *Haemophilia.* 2016;**22** Suppl 4:3-138. Poster PO-W-4. 11. Sumner MJ et al. *Haemophilia.* 2007;**13**(5):451-461. 12. Lentz SR et al. *J Blood Med.* 2014;**5**:1-3. 13. Sun B et al. *Br J Haematol.* 2019. doi: 10.1111/bjh.16128. [Epub ahead of print]. 14. Pardos-Gea J et al. *Haemophilia.* 2018;**24**(3):e163-e166. 15. Tiede A, Worster A. *Ann Hematol.* 2018;**97**(10):1889-1901. 16. Abshire T, Kenet G. *Haemophilia.* 2008;**14**(5):898-902. 17. Rexen P et al. *TH Open.* 2019;**3**:e45-e49. 18. Pollard D et al. *J Haem Pract.* 2017;**4**(1):1-5. 19. NovoSeven[®] Summary of Product Characteristics. 20. Hemlibra[®] Summary of Product Characteristics. 21. FEIBA[®] Summary of Product Characteristics. 22. Obizur[®] Summary of Product Characteristics. 23. Hedner U. *Blood Rev.* 2015;**29**(S1):S4-S8. 24. Demartis F et al. *TH Open.* 2017;**1**:e130-e138. 25. Lentz SR et al. *J Thromb Haemost.* 2014;**12**(8):1244-1253. 26. Di Minno G et al. *Haematologica.* 2015;**100**(8):1031-1037. 27. Mariani G et al. *Thromb Haemost.* 2013;**109**:238-247. 28. Hoffman M Dargaud Y. *J Thromb Haemost.* 2012;**10**:1478-1485. 29. Neufeld EJ et al. *Haemophilia.* 2011;**17**:650-656. 30. Neufeld EJ et al. *Haemophilia.* 2018;**24**(4):e275-e277.

To report any side effect(s) or for more medical info please contact us:

- E-mail: nngulfsafety@novonordisk.com
- Website: <http://www.novonordisk.com.sa>

To report any side effect(s) please contact the National Pharmacovigilance

- Centre (NPC):- E-mail: nngulfsafety@novonordisk.com
- SFDA call center: 19999 - E-mail: npc.drug@sfd.gov.sa
- Website: <https://ade.sfda.gov.sa/>

- In the event that there are comments on this materials, please contact SFDA: 19999

For more information about the product, please refer to the last approved Summary of product characteristics in KSA on Saudi Drugs Information system (SDI) website: (<https://sdi.sfda.gov.sa/>).

Do you remember your first NovoSeven® success story?

“

**I'll never forget
my first patient.
When his life was in
danger, I knew where
to turn for a fast
treatment.”^{1,2}**

NovoSeven® is indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgery or invasive procedures in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX, congenital haemophilia expected to have a high anamnestic response to factor VIII or factor IX, acquired haemophilia, congenital FVII deficiency, and Glanzmann's thrombasthenia with past or present refractoriness to platelet transfusions or where platelets are not readily available.¹

NovoSeven® is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis.¹

References:

1. NovoSeven® Summary of Product Characteristics.
2. Maahs J *et al. J Blood Med.* 2014;**5**:153–156.

To report any side effect(s) or for more medical info please contact us:

- E-mail: nngulfsafety@novonordisk.com
- Website: <http://www.novonordisk.com.sa>

To report any side effect(s) please contact the National Pharmacovigilance

Centre (NPC): - E-mail: nngulfsafety@novonordisk.com
- SFDA call center: 19999 - E-mail: npc.drug@sfd.gov.sa
- Website: <https://ade.sfd.gov.sa/>

- In the event that there are comments on this materials, please contact SFDA: 19999

For more information about the product, please refer to the last approved Summary of product characteristics in KSA on Saudi Drugs Information system (SDI) website: (<https://sdi.sfd.gov.sa/>).



INTERNATIONAL SOCIETY
OF PAEDIATRIC ONCOLOGY

SOP
ASIA 2025

**INTERNATIONAL
SOCIETY OF
PEDIATRIC
ONCOLOGY**

12nd - 15th Apr 2025

ALMAAREFA UNIVERSITY

RIYADH - KSA

Stronger Together



**THANK
YOU**

